BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tao H, Shi KH, Yang JJ, Huang C, Zhan HY, Li J. Histone deacetylases in cardiac fibrosis: current perspectives for therapy. Cell Signal 2014;26:521-7. [PMID: 24321371 DOI: 10.1016/j.cellsig.2013.11.037] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 3.9] [Reference Citation Analysis]
Number Citing Articles
1 Wu S, Lan J, Li L, Wang X, Tong M, Fu L, Zhang Y, Xu J, Chen X, Chen H, Li R, Wu Y, Xin J, Yan X, Li H, Xue K, Li X, Zhuo C, Jiang W. Sirt6 protects cardiomyocytes against doxorubicin-induced cardiotoxicity by inhibiting P53/Fas-dependent cell death and augmenting endogenous antioxidant defense mechanisms. Cell Biol Toxicol 2021. [PMID: 34713381 DOI: 10.1007/s10565-021-09649-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
2 Applegate TJ, Krafsur GM, Boon JA, Zhang H, Li M, Holt TN, Ambler SK, Abrams BA, Gustafson DL, Bartels K, Garry FB, Stenmark KR, Brown RD. Brief Report: Case Comparison of Therapy With the Histone Deacetylase Inhibitor Vorinostat in a Neonatal Calf Model of Pulmonary Hypertension. Front Physiol 2021;12:712583. [PMID: 34552503 DOI: 10.3389/fphys.2021.712583] [Reference Citation Analysis]
3 Kang GJ, Kim EJ, Lee CH. Therapeutic Effects of Specialized Pro-Resolving Lipids Mediators on Cardiac Fibrosis via NRF2 Activation. Antioxidants (Basel) 2020;9:E1259. [PMID: 33321955 DOI: 10.3390/antiox9121259] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
4 Gerthoffer W. Epigenetic Targets for Oligonucleotide Therapies of Pulmonary Arterial Hypertension. Int J Mol Sci 2020;21:E9222. [PMID: 33287230 DOI: 10.3390/ijms21239222] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
5 Gui HX, Peng J, Yang ZP, Chen LY, Zeng H, Shao YT, Mu X, Hao Q, Yang Y, An S, Guo XX, Xu TR, Liu Y. HDAC1-Smad3-mSin3A complex is required for Smad3-induced transcriptional inhibition of hepatocyte growth factor receptor in human lung cancers. Carcinogenesis 2021;42:587-600. [PMID: 33151304 DOI: 10.1093/carcin/bgaa112] [Reference Citation Analysis]
6 Blanquart C, Linot C, Cartron PF, Tomaselli D, Mai A, Bertrand P. Epigenetic Metalloenzymes. Curr Med Chem 2019;26:2748-85. [PMID: 29984644 DOI: 10.2174/0929867325666180706105903] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
7 Li WQ, Luo LD, Hu ZW, Lyu TJ, Cen C, Wang Y. PLD1 promotes dendritic spine morphogenesis via activating PKD1. Mol Cell Neurosci 2019;99:103394. [PMID: 31356881 DOI: 10.1016/j.mcn.2019.103394] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
8 Pardo-Jiménez V, Navarrete-Encina P, Díaz-Araya G. Synthesis and Biological Evaluation of Novel Thiazolyl-Coumarin Derivatives as Potent Histone Deacetylase Inhibitors with Antifibrotic Activity. Molecules 2019;24:E739. [PMID: 30791388 DOI: 10.3390/molecules24040739] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
9 Huang D, Cui L, Ahmed S, Zainab F, Wu Q, Wang X, Yuan Z. An overview of epigenetic agents and natural nutrition products targeting DNA methyltransferase, histone deacetylases and microRNAs. Food and Chemical Toxicology 2019;123:574-94. [DOI: 10.1016/j.fct.2018.10.052] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
10 Wang R, Lin J, Bagchi RA. Novel molecular therapeutic targets in cardiac fibrosis: a brief overview 1. Can J Physiol Pharmacol 2019;97:246-56. [PMID: 30388374 DOI: 10.1139/cjpp-2018-0430] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
11 Chang C, Li S, Chen Y, Huang S, Chen S, Chen Y. Histone deacetylase inhibition attenuates atrial arrhythmogenesis in sterile pericarditis. Translational Research 2018;200:54-64. [DOI: 10.1016/j.trsl.2018.06.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
12 Dong Y, Xu S, Liu J, Ponnusamy M, Zhao Y, Zhang Y, Wang Q, Li P, Wang K. Non-coding RNA-linked epigenetic regulation in cardiac hypertrophy. Int J Biol Sci 2018;14:1133-41. [PMID: 29989099 DOI: 10.7150/ijbs.26215] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
13 Lee TW, Lee TI, Lin YK, Kao YH, Chen YJ. Calcitriol downregulates fibroblast growth factor receptor 1 through histone deacetylase activation in HL-1 atrial myocytes. J Biomed Sci 2018;25:42. [PMID: 29776409 DOI: 10.1186/s12929-018-0443-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Zhang Y, Luo G, Zhang Y, Zhang M, Zhou J, Gao W, Xuan X, Yang X, Yang D, Tian Z, Ni B, Tang J. Critical effects of long non-coding RNA on fibrosis diseases. Exp Mol Med 2018;50:e428. [PMID: 29350677 DOI: 10.1038/emm.2017.223] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 7.3] [Reference Citation Analysis]
15 Muthiah R. Tropical Coronary Artery Disease and Arrhythmogenic Potentials—The Changing Pattern towards Endomyocardial Fibrosis—An Analysis. CRCM 2018;07:397-429. [DOI: 10.4236/crcm.2018.76036] [Reference Citation Analysis]
16 Bollag WB, Choudhary V, Zhong Q, Ding KH, Xu J, Elsayed R, Yu K, Su Y, Bailey LJ, Shi XM, Elsalanty M, Johnson MH, McGee-Lawrence ME, Isales CM. Deletion of protein kinase D1 in osteoprogenitor cells results in decreased osteogenesis in vitro and reduced bone mineral density in vivo. Mol Cell Endocrinol 2018;461:22-31. [PMID: 28811183 DOI: 10.1016/j.mce.2017.08.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
17 Niu Y, Wang T, Liu S, Yuan H, Li H, Fu L. Exercise-induced GLUT4 transcription via inactivation of HDAC4/5 in mouse skeletal muscle in an AMPKα2-dependent manner. Biochim Biophys Acta Mol Basis Dis 2017;1863:2372-81. [PMID: 28688716 DOI: 10.1016/j.bbadis.2017.07.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
18 Sharma A, Anumanthan G, Reyes M, Chen H, Brubaker JW, Siddiqui S, Gupta S, Rieger FG, Mohan RR. Epigenetic Modification Prevents Excessive Wound Healing and Scar Formation After Glaucoma Filtration Surgery. Invest Ophthalmol Vis Sci 2016;57:3381-9. [PMID: 27367506 DOI: 10.1167/iovs.15-18750] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
19 Grimaldi V, De Pascale MR, Zullo A, Soricelli A, Infante T, Mancini FP, Napoli C. Evidence of epigenetic tags in cardiac fibrosis. Journal of Cardiology 2017;69:401-8. [DOI: 10.1016/j.jjcc.2016.10.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 9.0] [Reference Citation Analysis]
20 Aslibekyan S, Claas S, Arnett D. Epigenetics in Cardiovascular Disease. Translating Epigenetics to the Clinic. Elsevier; 2017. pp. 135-57. [DOI: 10.1016/b978-0-12-800802-7.00006-x] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
21 Yang F, Peng S, Li Y, Su L, Peng Y, Wu J, Chen H, Liu M, Yi Z, Chen Y. A hybrid of thiazolidinone with the hydroxamate scaffold for developing novel histone deacetylase inhibitors with antitumor activities. Org Biomol Chem 2016;14:1727-35. [PMID: 26732459 DOI: 10.1039/c5ob02250a] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
22 Seok YM, Lee HA, Park KM, Hwangbo M, Kim IK. Lysine deacetylase inhibition attenuates hypertension and is accompanied by acetylation of mineralocorticoid receptor instead of histone acetylation in spontaneously hypertensive rats. Naunyn-Schmiedeberg's Arch Pharmacol 2016;389:799-808. [DOI: 10.1007/s00210-016-1246-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
23 Wang J, Hu X, Jiang H. HDAC inhibition: A novel therapeutic approach for attenuating heart failure by suppressing cardiac remodeling. Int J Cardiol 2016;214:41-2. [PMID: 27057972 DOI: 10.1016/j.ijcard.2016.03.188] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
24 Tao H, Yang JJ, Shi KH, Li J. Epigenetic factors MeCP2 and HDAC6 control α-tubulin acetylation in cardiac fibroblast proliferation and fibrosis. Inflamm Res 2016;65:415-26. [PMID: 26975406 DOI: 10.1007/s00011-016-0925-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
25 Tao H, Yang JJ, Hu W, Shi KH, Deng ZY, Li J. Noncoding RNA as regulators of cardiac fibrosis: current insight and the road ahead. Pflugers Arch 2016;468:1103-11. [PMID: 26786602 DOI: 10.1007/s00424-016-1792-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
26 Tao H, Yang J, Hu W, Shi K, Deng Z, Li J. MeCP2 regulation of cardiac fibroblast proliferation and fibrosis by down-regulation of DUSP5. International Journal of Biological Macromolecules 2016;82:68-75. [DOI: 10.1016/j.ijbiomac.2015.10.076] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
27 Jia H, François F, Bourien J, Eybalin M, Lloyd RV, Van De Water TR, Puel JL, Venail F. Prevention of trauma-induced cochlear fibrosis using intracochlear application of anti-inflammatory and antiproliferative drugs. Neuroscience 2016;316:261-78. [PMID: 26718602 DOI: 10.1016/j.neuroscience.2015.12.031] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
28 Wang J, Hu X, Jiang H. HDAC inhibition: A novel therapeutic target for attenuating myocardial ischemia and reperfusion injury by reversing cardiac remodeling. Int J Cardiol 2015;190:126-7. [PMID: 25918063 DOI: 10.1016/j.ijcard.2015.04.172] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
29 Wang ZY, Qin W, Yi F. Targeting histone deacetylases: perspectives for epigenetic-based therapy in cardio-cerebrovascular disease. J Geriatr Cardiol 2015;12:153-64. [PMID: 25870619 DOI: 10.11909/j.issn.1671-5411.2015.02.010] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
30 Hamm CA, Costa FF. Epigenomes as therapeutic targets. Pharmacol Ther 2015;151:72-86. [PMID: 25797698 DOI: 10.1016/j.pharmthera.2015.03.003] [Cited by in Crossref: 80] [Cited by in F6Publishing: 83] [Article Influence: 11.4] [Reference Citation Analysis]
31 Martinez SR, Gay MS, Zhang L. Epigenetic mechanisms in heart development and disease. Drug Discov Today. 2015;20:799-811. [PMID: 25572405 DOI: 10.1016/j.drudis.2014.12.018] [Cited by in Crossref: 63] [Cited by in F6Publishing: 67] [Article Influence: 9.0] [Reference Citation Analysis]
32 Comer BS, Ba M, Singer CA, Gerthoffer WT. Epigenetic targets for novel therapies of lung diseases. Pharmacol Ther 2015;147:91-110. [PMID: 25448041 DOI: 10.1016/j.pharmthera.2014.11.006] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 7.0] [Reference Citation Analysis]
33 Lkhagva B, Chang SL, Chen YC, Kao YH, Lin YK, Chiu CT, Chen SA, Chen YJ. Histone deacetylase inhibition reduces pulmonary vein arrhythmogenesis through calcium regulation. Int J Cardiol 2014;177:982-9. [PMID: 25449511 DOI: 10.1016/j.ijcard.2014.09.175] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
34 Tao H, Yang J, Chen Z, Xu S, Zhou X, Zhan H, Shi K. DNMT3A silencing RASSF1A promotes cardiac fibrosis through upregulation of ERK1/2. Toxicology 2014;323:42-50. [DOI: 10.1016/j.tox.2014.06.006] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 7.0] [Reference Citation Analysis]
35 Aslibekyan S, Claas SA, Arnett DK. Clinical applications of epigenetics in cardiovascular disease: the long road ahead. Transl Res 2015;165:143-53. [PMID: 24768945 DOI: 10.1016/j.trsl.2014.04.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
36 Lishnevsky M, Haudek SB. Epigenetic regulation of fibrocyte differentiation? J Mol Cell Cardiol 2014;69:85-7. [PMID: 24512845 DOI: 10.1016/j.yjmcc.2014.01.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
37 Zhang Y, Ren J. Targeting autophagy for the therapeutic application of histone deacetylase inhibitors in ischemia/reperfusion heart injury. Circulation 2014;129:1088-91. [PMID: 24396040 DOI: 10.1161/CIRCULATIONAHA.113.008115] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 6.6] [Reference Citation Analysis]